A5015424756- Tea Polyphenols and Effects
- Liver Disease Diagnosis and Treatment
- Cancer Risks and Factors
- Breast Cancer Treatment Studies
- Nutritional Studies and Diet
- Phytoestrogen effects and research
- Cancer, Lipids, and Metabolism
- Diet and metabolism studies
- Drug-Induced Hepatotoxicity and Protection
- Dietetics, Nutrition, and Education
- Nutrition, Genetics, and Disease
- Cancer-related Molecular Pathways
- Food, Nutrition, and Cultural Practices
- Colorectal Cancer Screening and Detection
- Digital Radiography and Breast Imaging
- Organic Food and Agriculture
- Ginkgo biloba and Cashew Applications
- Advanced Breast Cancer Therapies
University of Minnesota
2015-2017
Abstract Epidemiologic and animal studies suggest a protective role of green tea against breast cancer. However, the underlying mechanism is not understood. We conducted randomized, double-blinded, placebo-controlled phase II clinical trial to investigate whether supplementation with extract (GTE) modifies mammographic density (MD), as potential mechanism, involving 1,075 healthy postmenopausal women. Women assigned treatment arm consumed daily 4 decaffeinated GTE capsules containing 1,315...
Liver injury effects of green tea-based products have been reported in sporadic case reports. However, no study has examined systematically such adverse an unbiased manner. We the potential a high, sustained oral dose tea extract (GTE) on liver measures randomized, placebo-controlled, double-blinded phase II clinical trial, which enrolled 1,075 women with original aim to assess effect daily GTE consumption for 12 months biomarkers breast cancer risk. The current analysis 1,021 participants...
Abstract Background Green tea extract ( GTE ) may be involved in a favourable post‐prandial response to high‐carbohydrate meals. The catechol‐O‐methyltransferase COMT genotype modify these effects. We examined the acute effects of supplementation on meal by assessing appetite‐associated hormones and glucose homeostasis marker concentrations women who consumed 843 mg (−)‐epigallocatechin‐3‐gallate EGCG or placebo capsules for 11–12 months. Methods Sixty Caucasian post‐menopausal body mass...
The objective of this study was to monitor adverse events (AEs) in healthy postmenopausal women randomized receive either green tea extract (GTE) containing 840 mg (‐)‐epigallocatechin‐3‐gallate (EGCG)/day (n=538) or placebo (n=537) for one year. Data on AEs obtained by participant self‐report and hepatic panel assessment. were recorded graded using the National Cancer Institute's Common Terminology Criteria Adverse Events (CTCAE), v.4.03. 407 participants GTE group reported 1141 AEs; 391...
Background Green tea consumption has been associated with favorable changes in body weight and obesity‐related hormones, though it is unknown if this due to green polyphenols or caffeine. Objective We examined the impact of decaffeinated extract (GTE) containing 843 mg (−)‐epigallocatechin‐3‐gallate (EGCG) on anthropometric variables, obesity‐associated glucose homeostasis. Methods The Minnesota Tea Trial was a 12‐month randomized, double‐blind, placebo‐controlled clinical trial 937 healthy...
Background Green tea has been suggested to improve cardiovascular risk factors including circulating lipid parameters predominantly based on small and short randomized controlled trials. Data from long‐term intervention studies with relatively large sample size are lacking. Objective To determine the effects of daily green extract (GTE) supplementation high in epigallocatechin gallate (EGCG) for 12 months blood lipids healthy postmenopausal women U.S. Methods design This was an ancillary...
<div>Abstract<p>Liver injury effects of green tea–based products have been reported in sporadic case reports. However, no study has examined systematically such adverse an unbiased manner. We the potential a high, sustained oral dose tea extract (GTE) on liver measures randomized, placebo-controlled, double-blinded phase II clinical trial, which enrolled 1,075 women with original aim to assess effect daily GTE consumption for 12 months biomarkers breast cancer risk. The current...
<p>Supplemental Table S5 demonstrates the change of serum ALT and AST during intervention period from baseline in subgroups stratified by selected characteristics.</p>
<p>Supplemental Table S4 shows the grading of ALT during 12-month treatment period by level baseline liver function tests and interaction with assignment (GTE or Placebo).</p>
<p>Supplemental Table S7 shows ALT, AST, alkaline phosphatase and total bilirubin results self-reported symptoms for eight women whose ALT increased above 300 U/L over the course of treatment with GTE or placebo.</p>
<p>Supplemental Table S6 displays the ALT level among 40 women whose increased above 90 U/L over course of treatment with GTE or placebo.</p>
<p>Supplemental Table S1 shows the severity grading in Drug Induced Liver Injury from LIVERTOX produced by AIDS CTG.</p>
<p>Supplemental Table S2 shows the baseline mean concentrations of alanine aminotransferase (ALT) and aspartate (AST) in all participants subgroups stratified by selected characteristics study treatment status (GTE or placebo).</p>
<p>Supplemental Table S3 describes the characteristics at baseline among study participants in green tea extract group with and without ALT greater than 75 U/L.</p>
<p>Supplemental Table S7 shows ALT, AST, alkaline phosphatase and total bilirubin results self-reported symptoms for eight women whose ALT increased above 300 U/L over the course of treatment with GTE or placebo.</p>
<p>Supplemental Table S3 describes the characteristics at baseline among study participants in green tea extract group with and without ALT greater than 75 U/L.</p>